← Leaderboards
Melissa Mavers
Washington University
$832,680
Attributed
$832,680
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $333.1K · FY2020–24$500K$375K$250K$125K$0
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$832,680 · 1
By mechanism
K08$832,680 · 1
Top collaborators
No co-investigators on record.
Most similar at Washington University
Same institution · by research overlap
- John F Dipersio$33,235,840
- Timothy J Ley$36,060,228
- J Evan Sadler$26,812,449
- Daniel C Link$19,842,999
- Luis Francisco Zirnberger Batista$6,227,466
Others in their field
Other Emerging Leaders on “Engineered Gene”
- Yunda Huang · Fred Hutchinson Cancer Center$52,003,716
- Benjamin E Deverman · Broad Institute, Inc.$17,740,267
- Crystal Mackall · Children'S Hosp Of Philadelphia$16,367,876
- Jacqueline K White · Jackson Laboratory$11,525,170
- Afonso C Silva · University Of Pittsburgh At Pittsburgh$11,052,001
- Sandhya Vasan · Henry M. Jackson Fdn For The Adv Mil/Med$11,035,903
Research focus
Engineered GeneEngineered T CellsDisorder PreventionAntimicrobialAcute Graft Versus Host DiseaseAdvisory CommitteesAdoptive TransferCancer RelapseCareerCareer DevelopmentAutoimmunityCell PhysiologyCellsCellular ImmunologyAllogenicCellular TransductionClinical TrialsCytokineCytotoxicCytotoxic T-LymphocytesDesignDevelopment PlansCell InjuryEnsure
Grant awards (5)
Immunosuppressive human invariant natural killer T cells for prevention of graft-versus-host disease$166,536
K08 · FY2024 · HL · contact PI
Immunosuppressive human invariant natural killer T cells for prevention of graft-versus-host disease$166,536
K08 · FY2022 · HL · contact PI
Immunosuppressive human invariant natural killer T cells for prevention of graft-versus-host disease$166,536
K08 · FY2022 · HL · contact PI
Immunosuppressive human invariant natural killer T cells for prevention of graft-versus-host disease$166,536
K08 · FY2021 · HL · contact PI
Immunosuppressive human invariant natural killer T cells for prevention of graft-versus-host disease$166,536
K08 · FY2020 · HL · contact PI